At AHA 2024, clinical trial results were presented from the ongoing open-label extension trial, LIBERATE-OLE, involving ...

Presenting initial results from the company-sponsored Phase 1/2a study of [212Pb]VMT-α-NET in patients with RPT-naïve neuroendocrine tumors at the upcoming 2024 North American Neuroendocrine Tumor ...

Tokmanni Group Corporation Business Review Unaudited 15 November 2024 at 8:00 THIRD QUARTER 2024 HIGHLIGHTS Tokmanni Group's revenue grew by 14.3% (23.6%) and was EUR 416.3 ...

Krystal Biotech, Inc. (NASDAQ:KRYS) Q3 2024 Earnings Call Transcript November 4, 2024 Krystal Biotech, Inc. beats earnings expectations. Reported EPS is $0.909, expectations were $0.9. Operator: Thank ...

Globally trading companies depend on the analysis of export import data and customs data. This analysis offers insightful ...

The drug is the world’s first-ever CRISPR/Cas13 RNA-editing therapy for clinical use in treating neovascular age-related ...

Appointed Douglas Williams, Ph.D. as Chair of the Board of DirectorsFDA Clearance of Investigational New Drug Application (IND) for systemic ...

Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Ladies and gentlemen, greetings, and welcome to the KORU Medical ...

AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...

As a result, we are pleased to be raising our revenue and gross margin guidance for the second time this year, in addition to increasing our year-end cash balance target ... label and generate ...

The UK-based firm is developing its initial panel tests for Gram-negative bacteria with tests for Gram-positive bacteria and ...

Business Highlights & Milestones Completed enrollment in PEAK, a randomized, open-label, global Phase 3 trial evaluating ... CGT6297 has high oral bioavailability and low clearance across species, ...